Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Sep 02, 2024 12:23pm
80 Views
Post# 36205228

RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket billAugust 28, 2024 - The USPTO’s May 2024 proposed anti-patent thicket rule, which promotes competition by lowering the cost of challenging groups of patents linked by terminal disclaimers, is also proposed to result in reduced barriers to market entry. Under the proposed USPTO rule, “if you invalidate one, the whole thing falls,” 

On the legislative side, currently there are two major bipartisan bills working their way through Congress which seek to curb Big Pharma’s manipulation of the patent system, by filing multiple follow-on patents on variations of the same technology. Commony known as "evergreening".

https://www.biospace.com/policy/patent-thickets-in-federal-governments-crosshairs-as-election-2024-looms


<< Previous
Bullboard Posts
Next >>